期刊
REVIEWS ON RECENT CLINICAL TRIALS
卷 3, 期 3, 页码 212-216出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/157488708785700311
关键词
Renal cell carcinoma; tyrosine kinase inhibitor; antiangiogenic agents; ASCO 2007; combination regime; targeted therapies
Cytokine-based therapeutic approaches using interferon (IFN) and interleukin 2 (IL-2) were conventionally applied for the treatment of progressive RCC. Caused by the limited effectiveness of cytokine-based approaches in advanced renal cell carcinoma, new substances were needed. Among these, the targeted therapies, particularly the group of the tyrosine kinase inhibitors, are of main interest. At present, multikinase inhibitors and antiangiogenic agents (VEGFR, PDGFR-beta, and mTOR) are used in first-and second-line therapies of metastatic RCC in various clinical studies. This review presents and discusses the effectiveness of the most frequently used substances in mono-or combination regimes based on current data of the ASCO 2007.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据